BioLineRx to Release 2024 Annual Results
BioLineRx Ltd. (NASDAQ: BLRX), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies in oncology and rare diseases, is preparing for the release of its audited financial results for the fiscal year ended December 31, 2024. This announcement is set to take place on March 31, 2025, prior to the opening of the U.S. markets.
Upcoming Conference Call Details
The Company will host a conference call at 8:30 a.m. EDT, featuring insights from Philip Serlin, the Chief Executive Officer. This event represents a significant opportunity for investors and stakeholders to gain direct updates on the Company’s progress and financial standing.
To participate in the live conference call, individuals can dial +1-888-281-1167 from the U.S. or +972-3-918-0685 from international locations. Additionally, a live webcast will be available, along with a replay following the call, ensuring widespread access to vital information. Participants are encouraged to allow sufficient time before the call to access the necessary platforms and downloads to participate fully.
For those unable to attend the live session, dial-in replays will be available for a period following the call, making it easy for interested parties to catch up on what they may have missed.
About BioLineRx and Its Innovations
BioLineRx Ltd. is focused on delivering life-changing treatments in oncology and rare diseases. The company’s first approved treatment, APHEXDA® (motixafortide), is designed for assisting in stem cell mobilization prior to autologous transplantation in patients with multiple myeloma. This innovative product is currently being developed and commercialized in collaboration with Ayrmid Ltd. outside Asia and Gloria Biosciences within Asia.
The company utilizes its comprehensive expertise in areas such as development, regulatory affairs, manufacturing, and commercialization to enhance its promising pipeline. BioLineRx is committed to ensuring that its groundbreaking discoveries are effectively translated from laboratory research to treatment options available to patients.
Contact Information
For more insights and updates about BioLineRx, interested parties can explore further details at their official website. Here, one can find vital information on the company’s vision, operations, and initiatives in the biopharmaceutical landscape.
CONTACTS:
United States
Irina Koffler
LifeSci Advisors, LLC
[Email and contact number are provided through direct means for privacy.]
Israel
Moran Meir
LifeSci Advisors, LLC
[Email and contact number are provided through direct means for privacy.]
Frequently Asked Questions
What are the upcoming financial results announcement details?
BioLineRx is scheduled to release its 2024 annual results on March 31, 2025, before market opening.
Who will be presenting during the conference call?
Phil Serlin, the CEO of BioLineRx, will be presenting during the conference call.
How can I join the conference call?
You can dial +1-888-281-1167 in the U.S. or +972-3-918-0685 internationally to join the call.
Will the conference call be available for later listening?
Yes, a replay will be available approximately two hours after the live call.
What is BioLineRx's primary area of focus?
BioLineRx focuses on developing therapies in oncology and rare diseases, specifically through innovative treatments like APHEXDA®.
